Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · January 16, 2024

Neoadjuvant Atezolizumab Plus Chemotherapy for Gastric and Gastroesophageal Junction Adenocarcinoma

Nature Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Nature Medicine
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Nat. Med. 2024 Jan 08;[EPub Ahead of Print], YL Verschoor, J van de Haar, JG van den Berg, JW van Sandick, LL Kodach, JM van Dieren, S Balduzzi, C Grootscholten, ME IJsselsteijn, AAFA Veenhof, KJ Hartemink, MA Vollebergh, A Jurdi, S Sharma, E Spickard, EC Owers, A Bartels-Rutten, P den Hartog, NFCC de Miranda, ME van Leerdam, JBAG Haanen, TN Schumacher, EE Voest, M Chalabi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading